EFFICACY OF MURINE PLATELET RICH-PLASMA VERSUS SPIRAMYCIN IN TREATMENT OF CHRONIC TOXOPLASMOSIS INFECTED MICE | ||||
| Journal of the Egyptian Society of Parasitology | ||||
| Volume 52, Issue 2, August 2022, Page 267-278 PDF (1.53 MB) | ||||
| DOI: 10.21608/jesp.2022.257455 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| SHEREEN M. IBRAHIM; SABAH M. A. MOHAMED; HEBA H. M. FOAAD; HAYTHAM K. AHMAD; ASMAA M. F. AL-GHANDOUR | ||||
| Department of Parasitology, Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||||
| Abstract | ||||
| Apicomplexan parasite, Toxoplasma gondii, is an obligate intracellular parasite, infecting and replicating within nucleated cells in many homoeothermic organisms, mammals and birds with the possibility of causing serious health problems. Recent studies indicated several side effects to the current drugs like Pyrimethamine® & Sulfadiazine®. This work evaluated murine platelet rich plasma (PRP) efficacy versus Spiramycin® treating toxoplasmosis infected mice parasitological, biochemical and histopathological studies. Fifty five immunocompetent male mice were divided into 5 groups of 11 mice each. G1: non-infected control, G2: infected non-treated control, G3: infected and treated with spiramycin, G4: infected and treated with murine PRP, and G5: infected and treated with combined spiramycin and PRP. Spiramycin and PRP treated mice gave the highest reduction in Toxoplasma tissue cysts number, lowest level of serum malondialdehyde (MDA) and marked pathological improvement. | ||||
| Keywords | ||||
| Mice; Toxoplasma gondii; Platelet rich plasma; Spiramycin; Malondialdehyde | ||||
|
Statistics Article View: 126 PDF Download: 155 |
||||
